BridgeBio Pharma (BBIO) – Research Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of BridgeBio Pharma (NASDAQ: BBIO) recently:

  • 6/5/2024 – BridgeBio Pharma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.
  • 5/30/2024 – BridgeBio Pharma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.
  • 5/28/2024 – BridgeBio Pharma had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $70.00 price target on the stock.
  • 5/28/2024 – BridgeBio Pharma had its price target lowered by analysts at UBS Group AG from $51.00 to $47.00. They now have a “buy” rating on the stock.
  • 5/20/2024 – BridgeBio Pharma had its price target lowered by analysts at HC Wainwright from $47.00 to $43.00. They now have a “buy” rating on the stock.
  • 5/14/2024 – BridgeBio Pharma is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $50.00 price target on the stock.
  • 5/13/2024 – BridgeBio Pharma was upgraded by analysts at Evercore ISI to a “strong-buy” rating.

BridgeBio Pharma Trading Down 0.3 %

BridgeBio Pharma stock opened at $27.05 on Monday. The company has a 50-day moving average price of $27.60 and a 200 day moving average price of $32.06. BridgeBio Pharma, Inc. has a 12-month low of $14.78 and a 12-month high of $44.32. The stock has a market cap of $5.06 billion, a P/E ratio of -8.40 and a beta of 1.08.

BridgeBio Pharma (NASDAQ:BBIOGet Free Report) last posted its earnings results on Thursday, May 2nd. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.35. The business had revenue of $211.12 million for the quarter, compared to analyst estimates of $140.06 million. As a group, analysts forecast that BridgeBio Pharma, Inc. will post -3.2 EPS for the current year.

Insider Activity at BridgeBio Pharma

In related news, Director Randal W. Scott sold 1,000 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $28.84, for a total value of $28,840.00. Following the sale, the director now owns 5,500 shares in the company, valued at approximately $158,620. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 24.66% of the stock is owned by insiders.

Institutional Trading of BridgeBio Pharma

A number of large investors have recently modified their holdings of the stock. Diversified Trust Co raised its holdings in BridgeBio Pharma by 2.5% in the third quarter. Diversified Trust Co now owns 17,111 shares of the company’s stock valued at $451,000 after acquiring an additional 411 shares in the last quarter. American International Group Inc. raised its holdings in shares of BridgeBio Pharma by 1.0% in the 1st quarter. American International Group Inc. now owns 57,491 shares of the company’s stock valued at $1,778,000 after purchasing an additional 565 shares in the last quarter. Amalgamated Bank lifted its position in shares of BridgeBio Pharma by 3.8% during the 3rd quarter. Amalgamated Bank now owns 15,775 shares of the company’s stock worth $416,000 after purchasing an additional 576 shares during the last quarter. Parkman Healthcare Partners LLC grew its stake in shares of BridgeBio Pharma by 0.7% during the fourth quarter. Parkman Healthcare Partners LLC now owns 100,734 shares of the company’s stock worth $4,067,000 after purchasing an additional 734 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of BridgeBio Pharma by 1.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 65,773 shares of the company’s stock worth $2,655,000 after purchasing an additional 904 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

Further Reading

Receive News & Ratings for BridgeBio Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.